Researcher Profile

Researcher Profile

David Waning, PhD

David Waning, PhD

Associate Professor, Department of Cellular and Molecular Physiology
Scientific Program:Next-Generation Therapies
dlw83@psu.edu
View Website

Research Interests

Dr. David Waning's research focuses on the emerging importance of bone-muscle crosstalk in aging and disease.

The overarching goal of his research program is to discover and characterize molecular mechanisms that impair musculoskeletal health in disease and aging. Bone and muscle are tightly coupled during growth and development, and also during aging and disease yet the cellular and molecular mechanisms linking these two tissues are not well understood. The Waning lab is developing novel therapeutic approaches that improve musculoskeletal health in pre-clinical models of cancer and chemotherapy-induced sequelae, osteoporosis and aging.

The major aims of Dr. Waning's research are to identify and characterize signal mediators of bone-muscle crosstalk that affect musculoskeletal health. He is especially interested in identifying targets of oxidative stress that affect bone and muscle function; understanding muscle weakness in cachexia; cachexia and the relative contribution of muscle wasting and contractile dysfunction; and bone-muscle crosstalk in rare bone diseases.

  • Bone and Bones
  • Muscles
  • Neoplasms
  • Muscle Weakness
  • Skeletal Muscle
  • Proteins
  • Neoplasm Metastasis
  • Bone Neoplasms
  • Drug Therapy
  • Breast Neoplasms
  • Cachexia
  • DNA Damage

Recent Publications

2022

Stauch, CM, Fanburg-Smith, JC, Walley, KC, King, JL, Murie, B, Kim, M, Koroneos, Z, Waning, D, Elfar, JC & Aynardi, MC 2022, 'Animal model detects early pathologic changes of Charcot neuropathic arthropathy', Annals of Diagnostic Pathology, vol. 56, 151878. https://doi.org/10.1016/j.anndiagpath.2021.151878
Hain, BA & Waning, DL 2022, 'Electroporation of Plasmid DNA into Mouse Skeletal Muscle', Journal of Visualized Experiments, vol. 2022, no. 182, e63916. https://doi.org/10.3791/63916

2021

Wilcox-Hagerty, J, Xu, H, Hain, BA, Arnold, AC & Waning, DL 2021, 'Bone metastases induce metabolic changes and mitophagy in mice', Experimental Physiology, vol. 106, no. 2, pp. 506-518. https://doi.org/10.1113/EP089130
Hain, BA, Xu, H & Waning, DL 2021, 'Loss of REDD1 prevents chemotherapy-induced muscle atrophy and weakness in mice', Journal of Cachexia, Sarcopenia and Muscle, vol. 12, no. 6, pp. 1597-1612. https://doi.org/10.1002/jcsm.12795
Hain, BA, Xu, H, VanCleave, AM, Gordon, BS, Kimball, SR & Waning, DL 2021, 'REDD1 deletion attenuates cancer cachexia in mice', Journal of applied physiology, vol. 131, no. 6, pp. 1718-1730. https://doi.org/10.1152/japplphysiol.00536.2021

2020

Hain, BA, Narasimhan, A, Ballinger, TJ, Guise, TA & Waning, DL 2020, Cancer-associated muscle dysfunction. in Encyclopedia of Bone Biology. Elsevier, pp. 379-389.
Chakraborty, N, Waning, DL, Gautam, A, Hoke, A, Sowe, B, Youssef, D, Butler, S, Savaglio, M, Childress, PJ, Kumar, R, Moyler, C, Dimitrov, G, Kacena, MA & Hammamieh, R 2020, 'Gene-Metabolite Network Linked to Inhibited Bioenergetics in Association With Spaceflight-Induced Loss of Male Mouse Quadriceps Muscle', Journal of Bone and Mineral Research, vol. 35, no. 10, pp. 2049-2057. https://doi.org/10.1002/jbmr.4102

2019

Waning, DL, Guise, TA & Mohammad, KS 2019, 'A “Connexin” Responsible for the Fatal Attraction of Cancer to Bone', Cell Metabolism, vol. 29, no. 1, pp. 6-8. https://doi.org/10.1016/j.cmet.2018.12.014
Sturgeon, KM, Mathis, KM, Rogers, CJ, Schmitz, KH & Waning, DL 2019, 'Cancer- and Chemotherapy-Induced Musculoskeletal Degradation', JBMR Plus, vol. 3, no. 3, e10187. https://doi.org/10.1002/jbm4.10187
Huot, JR, Essex, AL, Gutierrez, M, Barreto, R, Wang, M, Waning, DL, Plotkin, LI & Bonetto, A 2019, 'Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles', Cancers, vol. 11, no. 4, 571. https://doi.org/10.3390/cancers11040571
Hain, BA, Jude, B, Xu, H, Smuin, DM, Fox, EJ, Elfar, JC & Waning, DL 2020, 'Zoledronic Acid Improves Muscle Function in Healthy Mice Treated with Chemotherapy', Journal of Bone and Mineral Research, vol. 35, no. 2, pp. 368-381. https://doi.org/10.1002/jbmr.3890

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)